Vol:25 | No:06 - DiabetesontheNet

This site is intended for healthcare professionals only

Diabetes &
Primary Care

Vol:25 | No:06
Nov 2024

Filter:

Editorial: New opportunities to support those New Year’s resolutions

The New Year is the perfect time to engage people with new invitations to attend type 2 diabetes and other wellbeing services.

Page: 179

The NHS T2Day (Type 2 Diabetes in the Young) programme: Addressing unmet need, improving awareness and building evidence

Providing additional clinical support to adults aged under 40 with type 2 diabetes, tailored to their individual needs.

Page: 181

Q&A: Breaking the cycle – Empowering healthcare professionals to overcome stigma in diabetes care

Deborah Christie outlines new research on diabetes stigma and discusses how healthcare professionals can reduce its incidence and impact.

Page: 183

Interactive case study: Primary prevention of cardiovascular disease and use of statins

Assessing cardiovascular risk and using statins to lower it.

Page: 187

At a glance factsheet: Polycystic ovary syndrome (PCOS)

When to suspect, how to diagnose and key messages on management.

Page: 189

Engaging with and optimising care for people under age 50 years with type 2 diabetes: The DiaST model of care

Embedding processes to engage with this hardly reached group leads to improved care process attainment.

Page: 193

Diabetes Distilled: Reaching a XENITH in cardiorenal protection

Phase 2b study demonstrates significant reductions in uACR with developmental drug zibotentan plus dapagliflozin, compared with dapagliflozin alone.

Page: 199

Diabetes Distilled: MACE risk higher in newly diagnosed type 2 diabetes treated with lifestyle alone

Foregoing therapies to reduce glucose, lipids and BP immediately after diagnosis increases MACE risk even if target glycaemic control is achieved.

Page: 201

Diabetes Distilled: DELIVERing reassurance that early eGFR reductions with SGLT2 inhibitors should not prompt drug discontinuation

Initial eGFR reductions of >10% when starting SGLT2 inhibitors are not associated with adverse cardiovascular or renal outcomes.

Page: 205

Diabetes Distilled: “Twincretin” tirzepatide significantly SURPASSes comparator effects on glucose, weight and quality of life

Will this highly effective new agent change current treatment guidelines, especially with regard to glycaemic and weight loss targets?

Page: 209

LATEST ARTICLES

Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity

Editorial: Type 2 diabetes, CVD, CKD, dementia and health inequality: Adopting a preventative approach

The dialysis timebomb: Why preventing kidney disease is everyone’s responsibility

Conference over coffee: Oncology, end-of-life care, psychology and insulin dilemmas

How to follow up gestational diabetes

Prescribing pearls: A guide to pioglitazone

Interactive case study: Antiplatelet treatment in diabetes

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;